Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 250 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patient Directed Standard of Care Clear all
Completed Phase 1Phase 2 Interventional

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

NCT00284817
View directory record Official record
Conditions
Cancer
Interventions
MEDI-522
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

NCT06681220
View directory record Official record
Conditions
Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
Stenoparib/Temozolomide, Lurbinectedin
Combination Product · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Phenotyping Acute Pain for Discovery Research and Directed Therapeutics

NCT02322996
View directory record Official record
Conditions
Post op Pain
Interventions
questionnaires
Other
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Training in Patients With Lower Extremity Fractures

NCT06496035
View directory record Official record
Conditions
Tibial Fractures, Lower Extremity Fracture
Interventions
Blood Flow Restriction with low load exercise, Therapeutic Exercise
Device · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

NCT06593314
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant

NCT05540340
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Interventions
Pharmacokinetics
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Terminated Not applicable Interventional

Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Spine Surgery

NCT01124474
View directory record Official record
Conditions
Surgical Procedures, Operative
Interventions
goal directed therapy
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Not applicable Interventional Results available

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)

NCT05275920
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care

NCT03715283
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease
Interventions
Home Ankle Strengthing Program, Standard of Care
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions
Tagraxofusp, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

NCT02119156
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Manhasset, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Sep 30, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Terminated No phase listed Observational

An In-vitro Standardization of B Cell Elispot Assays

NCT01334281
View directory record Official record
Conditions
Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02101385
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Breast Cancer
Interventions
Genomically Directed Monotherapy, Observation/Standard Therapy
Drug · Other
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 10:46 AM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Smartstep Smartphone PAD

NCT03479255
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Smartphone-enabled structured exercise therapy (SE-SET), Standard exercise therapy
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

NCT03621696
View directory record Official record
Conditions
HPV Related Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Intensity modulated radiation therapy, Intensity modulated proton therapy, Surgery, FACT-H&N, MD Anderson Dysphagia Inventory, University of Michigan Xerostomia Index, Scale of Subjective Total Taste Acuity, Neck Dissection Impairment Index
Drug · Radiation · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Patient Decision Aid in Immediate Postpartum Contraceptive Counseling

NCT03088397
View directory record Official record
Conditions
Contraception
Interventions
Patient Decision Aid, Website, Shared- Decision Making Counseling
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

NCT02476786
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
Interventions
FACT-B, Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen, Archived tissue collection
Behavioral · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
70 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

NCT04045470
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Interventions
Microdevices, Standard of care therapy, Standard of care systemic therapy
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 30, 2026, 10:46 AM EDT
Not yet recruiting Phase 2 Interventional

Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer

NCT07836712
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cholecalciferol, Computed Tomography, Desloratadine, Immunotherapy, Infusion Procedure, Magnesium Sulfate, Magnetic Resonance Imaging, Propranolol
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 10:46 AM EDT
Completed Not applicable Interventional

EHR-embedded OCDT in Breast or GI Cancer

NCT03858712
View directory record Official record
Conditions
Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions
Active Care Team Alert, Passive Care Team Alert
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 30, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 30, 2026, 10:46 AM EDT